Table 5.

Effects of supplementation with Ca salts of of PFAD (n = 14) or EPA + DHA (n = 14) during the last 50 d of gestation on lamb BW, ADG, and plasma concentrations of glucose and NEFA measured on d 1 (lambing), 30, and 60, and insulin and adropin measured on d 60

Item	Treatment1		SEM	P-value
	PFAD	EPA + DHA		Trt	Day	Trt*Day
BW2, kg	15.8	16.4	0.36	0.22	<0.001	0.50
ADG3, kg/d	0.32	0.34	0.02	0.21	<0.001	0.52
Plasma glucose, mM	5.20	5.35	0.167	0.50	<0.001	0.87
Plasma NEFA, µEq/L	514.48	493.39	23.987	0.52	<0.001	0.65
Insulin d 60, μg/mL	0.22	0.25	0.029	0.59	-	-
Adropin d 60, ng/mL	3.55	3.83	0.584	0.72	-	-

¹PFAD, EnerGII as a source of palmitic and oleic acids (Virtus Nutrition LLC); EPA + DHA, StrataG113 as a source of eicosapentaenoic acid and docosahexaenoic acids (Virtus Nutrition LLC).

²Average BW is reported due to the nonsignificant treatment by day interaction.

³ADG was calculated for d 1 to 30, and d 30 to 60. A treatment by day interaction was nonsignificant, so the average ADG is reported.